Amoy Diagnostics Co. Ltd.

History

Year	Detail
2008	Dr. Xiaoming Zhang founded Amoy Diagnostics with a vision to advance molecular diagnostics in oncology. The company specializes in developing innovative cancer detection solutions and personalized medicine.
2015	Amoy Diagnostics Co. Ltd. and Illumina, Inc. collaborated to accelerate the adoption of precision medicine and targeted therapies in China.
2016	Merck, a science and technology company, collaborated with the company to develop and commercialize liquid biopsy RAS biomarker tests for patients with static colorectal cancer (mCRC).
2017	Boehringer Ingelheim and AmoyDx collaborated to commercialize a new blood-based EGFR mutation test for patients with advanced non-small cell lung cancer (NSCLC). The test was developed using AmoyDx real-time polymerase chain reaction (PCR) technology, SuperARMS, and made available in China in 2017.
2019	The company partnered with Sanomics Limited, which provides genomics tests in Hong Kong and worldwide to deliver multi-gene tests for screening patients who benefit from targeted therapy in Hong Kong and Macau.
2019	The company partnered with PREMIA Holdings Ltd. to provide large-scale cancer patient screening in Asia to support LOXO-292 RET inhibitor clinical development leveraging AmoyDx’s proprietary multi-gene polymerase chain reaction (PCR) and next-generation sequencing (NGS) panels to identify patients with this rare genetic alteration.
2019	The company entered into a partnership with Eisai Co., Ltd., a Japanese pharmaceutical company, to develop and register companion diagnostic tests.
2020	The company collaborated with Amgen Inc. to develop Companion Diagnostic (CDx) tests supporting an investigational molecule within Amgen’s oncology portfolio.
2020	Amoy Diagnostics Co., Ltd. collaborated with Janssen (China) Research & Development Center, a Division of Johnson & Johnson (China) Investment Ltd., to develop an oncology companion diagnostic (CDx) test based on AmoyDx's NGS platform.
2020	The company collaborated with AstraZeneca to work together for the molecular diagnosis of patients with cancer, particularly in breast cancer, ovarian cancer, and prostate cancer patients.
2020	AmoyDx collaborated with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepotinib.
2020	The company collaborated with Haihe Pharmaceutical to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor Glumetinib.
2022	AmoyDx and PREMIA Holdings Ltd. commercially launched the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companion diagnostic for multiple anti-cancer agents.
2022	AmoyDx collaborated with Pierre Fabre to develop Companion Diagnostic (CDx) kits in China, supporting encorafenib and binimetinib marketing authorization applications.
2022	The company signed an agreement with HUTCHMED Ltd., a commercial-stage biopharmaceutical company, to jointly promote the development of molecular diagnostics for the Osimertinib/Savolitinib Combo treatment for NSCLC in the Chinese market.
2022	The company signed a master collaboration agreement with AstraZeneca regarding the development and commercialization of AmoyDx assays, which cover any indication or biomarker for companion diagnostic (CDx) use with AstraZeneca medicines globally.
2023	The company collaborated with AstraZeneca to develop a HER2 Companion Diagnostic for lung cancer in China.
2024	The company collaborated with Boehringer Ingelheim to develop a Companion Diagnostic (CDx) kit to identify non-small cell lung cancer (NSCLC) patients most likely to benefit from targeted therapy.
2024	AmoyDx and Servier entered a collaboration to develop an IDH1/2 companion diagnostic test for diffuse glioma in China.